Pharmacologic Treatment Plan and Justification The current state of affairs is that the patient is a 50-year-old male wi

Pharmacologic Treatment Plan and Justification

The current state of affairs is that the patient is a 50-year-old male with a three-year history of hypertension, and his current blood pressure reading is 160/98 mmHg, which fits into the ACC/AHA hypertension range Class 2. He is also having Type 2 diabetes which is well treated with metformin and high cholesterol which is controlled by atorvastatin. Since this patient has both hypertension and diabetes, he carries an elevated risk of cardiovascular diseases, and it is evident that pharmacologic treatment is necessary to alleviate it in addition to lifestyle changes.

The first line of choice is an angiotensin-converting enzyme (ACE) inhibitor like lisinopril 10 mg PO. ACE inhibitors have been found to be effective in reducing blood pressure besides having renal protection which is essential in patients with diabetes. They help in curbing cases of cardiovascular events as well. In the case of patient being intolerant of ACE inhibitors, an angiotensin II receptor blocker (ARB) such as losartan 50 mg daily should also be given since it has a similar efficacy profile and the usual side effects of increased cough is absent. Such agents are especially suitable in those individuals with hypertension and diabetes since, they decrease microalbuminuria and deterioration of diabetic nephropathy. The choice of lisinopril can also be explained by the existing evidence and clinical recommendations in the form of the American Diabetes Association (2024) that promote the use of ACE inhibitors or ARBs as a first-line drug in the treatment of diabetic patients with hypertension.

It is advised that the patient remains on metformin 500 mg formulation, two times per day since there is no contraindication combining metformin and an ACE inhibitor but the kidney should be monitored. The 20 mg of atorvastatin daily should not be excluded as well since it copes well with dyslipidemia which is another cardiovascular risk profile element in him. Both metformin and ACE inhibitors can impact the kidney functions; therefore, it would be reasonable to monitor the serum creatinine and estimated glomerular filtration rate (eGFR) regularly.

Monitoring and Safety Considerations

In order to guarantee both the effectiveness and the safety of the newly proposed antihypertensive treatment, there are a number of parameters, which need to be investigated on a regular basis. The first aim is to get the patient with a blood pressure level lower than 130/80 mmHg based on the recommendations of the ACC/AHA and the American Diabetes Association. At every clinical visit, blood pressure must be measured whereas at home, they should monitor the blood pressure to identify changes and response to therapy.

The test of Renal function, such as serum creatinine and eGFR, should be collected prior to the start of LISINOPRIL, and within 1-2 weeks of the start of LISINOPRIL treatment, and thereafter periodically. This is necessary as ACE inhibitors have a potential of leading to an acute kidney functional change especially among patients who are diabetics. Also, there is a need to monitor serum potassium since hyperkalemia may occur, which is a known side effect of ACE inhibitors. Dizziness can occur as well, in particular, when a patient takes the first dose, and a consistent dry cough. In unusual instances, lisinopril can instigate angioedema, in which case, it would have to be stopped instantly and replaced by an ARB.

The lipid profile and HbA1c of a patient must further be monitored to determine that his or her dyslipidemia and glycemia are in good control respectively. These and other steps, such as the monitoring of blood pressure, will help to get a full picture of the cardiovascular risk management by a patient.

Patient Education and Counseling

Education of patients is highly significant in encouraging compliance not only to medication but also providing long term control of hypertension. The patient will be explained that every drug prescribed has to be administered according to what it is meant to administer and that he should not abandon any medication without talking to the healthcare provider. The side effects of the drug lisinopril that includes dry cough, dizziness or swellings of the lips or even the face must be appropriately explained and positive directions passed on to the patient on reporting the symptoms when they start showing up.

Pharmacologic treatment of the condition is also accompanied by a high degree of lifestyle changes. It is imperative that the patient should be counseled on the consumption of the DASH ( Dietary Approaches to Stop Hypertension) diet which is aimed at low sodium diet (less than 1500 mg per day), an increase in intake of fruits, and low-fat dairy products. His physical activity should be at least 150 minutes of moderate-intensity exercise per week and he should strive to lose 5-10 percent body weight which may help in correcting the blood pressure level besides lowering the level of glucose in the body.

It would as well assist the patient to make sure that he or she does not take more than two standard drinks in a day, and that should he or she be a smoker, he or she should forsake the process of acquiring the vice. Follow up visits should be applied frequently to determine the success of the treatment, investigate any side effects and also to motivate the patient to commitment with medication and the lifestyle change. The treatment of the hypertension in the patient presented should be achieved individually through pharmacologic treatment, patient-centered education, and monitoring, because together the mentioned forms of treatment will allow the healthcare provider to treat such a patient in future and reduce the likelihood of incidents of cardiovascular complications.

References

American Diabetes Association. (2024). Standards of Medical Care in Diabetes—2024. Diabetes Care, 47(Suppl 1), S1–S346. https://doi.org/10.2337/dc24-Sint

Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., ... & Filippatos, G. (2021). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England Journal of Medicine, 384(24), 2219–2229. https://doi.org/10.1056/NEJMoa2025845

Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology, 71(19), e127–e248. https://doi.org/10.1016/j.jacc.2017.11.006

Williams, B., Mancia, G., Spiering, W., et al. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39(33), 3021–3104. https://doi.org/10.1093/eurheartj/ehy339